OverviewChartNewsTraderScreen

Morgan Stanley Knock-Out Novo-Nor.../  DE000MB16KT3  /

EUWAX
5/20/2024  4:26:24 PM Chg.+0.20 Bid7:55:46 PM Ask7:55:46 PM Underlying Strike price Expiration date Option type
11.86EUR +1.72% 12.05
Bid Size: 500		 12.10
Ask Size: 500		 NOVO-NORDISK NAM.B D... 467.3038 DKK 12/31/2078 Call
GlobeNewswire 5/15 Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Cl...
GlobeNewswire 5/15 Aeterna Zentaris Reports First Quarter 2024 Financial Results
GlobeNewswire 5/14 Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...
GlobeNewswire 5/9 US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire 5/7 Vect-Horus to Take Part in a Roundtable Discussion at Viva Technology Conference
TeleTrader 4/25 Europe opens mostly down after corporate earnings
GlobeNewswire 4/22 Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to...
GlobeNewswire 4/22 SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into cli...
GlobeNewswire 4/22 SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into cli...
GlobeNewswire 4/11 Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
GlobeNewswire 4/2 Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire 4/2 Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
GlobeNewswire 3/28 Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategi...
GlobeNewswire 3/27 Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completio...
GlobeNewswire 3/25 Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the ...
GlobeNewswire 3/18 Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ ...
GlobeNewswire 3/15 American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire 3/15 University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated...
GlobeNewswire 3/12 Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program...
GlobeNewswire 3/12 ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOA...
GlobeNewswire 3/11 FUJIFILM Diosynth Biotechnologies Appoints Richard McAvoy as Chief Financial Officer
GlobeNewswire 3/7 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. -...
GlobeNewswire 3/7 Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Car...
GlobeNewswire 3/1 SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire 2/28 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. -...